Adrenomedullin
Evidence: CCardiovascular / Vascular
Evidence Snapshot
Regulatory Context
This page summarizes research on the peptide and does not imply that the peptide is an FDA-approved drug or approved for a particular indication. Molecule-specific regulatory status requires verification against official regulatory records.
Research Takeaway
Adrenomedullin is a distinct mature human peptide and must not be merged with Adrenomedullin-2/Intermedin, CGRP, calcitonin, amylin, or proadrenomedullin-derived fragments.
Evidence boundary: Shared receptor-family or structural relationships do not establish molecular identity.
See all 6 evidence claims →Quick Summary
Adrenomedullin is an endogenous vasoactive peptide with a substantial direct-human infusion literature. Controlled studies demonstrate clear acute hemodynamic and neurohormonal activity, but the evidence base is much stronger for human pharmacology than for durable clinical efficacy.
Mechanism & Research Overview
Adrenomedullin is an endogenous vasoactive peptide with a substantial direct-human infusion literature. Controlled studies demonstrate clear acute hemodynamic and neurohormonal activity, but the evidence base is much stronger for human pharmacology than for durable clinical efficacy.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Adrenomedullin is a distinct mature human peptide and must not be merged with Adrenomedullin-2/Intermedin, CGRP, calcitonin, amylin, or proadrenomedullin-derived fragments.
Does not establish
Evidence boundary: Shared receptor-family or structural relationships do not establish molecular identity.
Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers
Supported
Direct IV Adrenomedullin administration in controlled human studies produces measurable cardiovascular effects, including reductions in arterial pressure and increases in cardiac output or cardiac index.
Does not establish
Evidence boundary: These are primarily acute hemodynamic/pharmacology findings and do not establish long-term therapeutic efficacy.
Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers; Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension
Supported
Small human studies in heart failure and pulmonary hypertension reported acute hemodynamic and neurohormonal responses to Adrenomedullin infusion.
Does not establish
Evidence boundary: Small experimental cohorts and surrogate hemodynamic endpoints do not establish reduced mortality, hospitalization, or durable disease benefit.
Sources: Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension
Supported
A randomized phase 1 study evaluated the safety, tolerability, and pharmacokinetics of prolonged Adrenomedullin infusion in healthy men.
Does not establish
Evidence boundary: Phase 1 tolerability cannot define long-term or population-wide safety.
Supported
Adrenomedullin's human evidence is stronger for direct pharmacology and hemodynamics than for durable therapeutic outcomes.
Sources: Adrenomedullin: a hypotensive hormone in man; Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers; Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure; Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension; Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial
Supported
No molecule-specific regulatory conclusion is frozen for native Adrenomedullin in Stage 2A.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Hypotension and reflex/sympathetic cardiovascular responses are plausible from direct human hemodynamic studies.Safety Consideration
Acute infusion may increase heart rate and neurohormonal activation even when arterial pressure falls.Safety Consideration
Long-term safety and durable therapeutic benefit remain incompletely established by the frozen source set.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial (2020):
- Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension (2000):
- Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers (2000):
- Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure (2000):
- Adrenomedullin: a hypotensive hormone in man (1997):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial | 2020 | Healthy males; randomized double-blind phase 1; placebo and multiple IV infusion rates | Evaluated 12-hour Adrenomedullin infusion pharmacodynamics, tolerability, and safety across multiple dose groups. | ||
| Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension | 2000 | 13 patients with precapillary pulmonary hypertension | Infusion increased cardiac index and reduced pulmonary vascular resistance/systemic pressure; aldosterone decreased. | ||
| Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers | 2000 | Eight healthy volunteers; randomized placebo-controlled crossover | Acute infusion increased cardiac output and heart rate, lowered diastolic pressure, stimulated renin/norepinephrine/prolactin, and did not significantly increase natriuresis. | ||
| Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure | 2000 | Seven CHF patients and seven healthy subjects, with placebo controls | Acute infusion increased cardiac index, reduced filling pressure and arterial pressure, and increased urine/sodium excretion; aldosterone fell in CHF patients. | ||
| Adrenomedullin: a hypotensive hormone in man | 1997 | Eight healthy male subjects; placebo-controlled randomized study | IV human Adrenomedullin reduced arterial pressure at studied doses; renal/electrolyte effects were limited under the protocol. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for Adrenomedullin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.